In a decisive move to counter critical domestic medicine shortages caused by global macroeconomic headwinds, the Department of Pharmaceuticals (DoP) has granted an in-principle approval to the National Pharmaceutical Pricing Authority (NPPA) to upwardly revise the ceiling prices of four essential drug formulations, including crucial life-saving oncology medications.
The swift regulatory intervention follows serious p concerns raised by frontline healthcare providers and premier medical institutions such as the Tata Memorial Cancer Hospital regarding the widespread domestic scarcity of pivotal platinum-based chemotherapy agents.
An evaluation revealed that the supply blockages were primarily driven by external macroeconomic constraints. The ongoing West Asia geopolitical crisis has triggered an exponential rise in the cost of raw platinum globally. When compounded by currency fluctuations and import logistics overheads, local drug manufacturers faced steep, production losses under the previous rigid price caps mandated by the Drug Prices Control Order (DPCO), 2013, ultimately forcing a suspension of production operations.
To incentivize immediate resumption of manufacturing and ensure Indian patients maintain unhindered access to essential therapies, the NPPA has been authorized to restructure the pricing dynamics under extraordinary provisions. The targeted price adjustment is projected to range between 10% and 50% above the last fixed baseline, contingent upon an ongoing empirical evaluation of verifiable raw material invoices submitted by active pharmaceutical manufacturer.
Written by: Pragna Biswas
Graphics by: Mainak Sen
